Benralizumab for Asthma
(CHINOOK Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication.Patients who complete treatment will enter 4 weeks follow-up period.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications. However, you must be on a high-dose inhaled corticosteroid plus a long-acting B2-agonist for at least 3 months before joining the trial.
Is Benralizumab safe for humans?
How is the drug Benralizumab different from other asthma treatments?
Benralizumab is unique because it is a monoclonal antibody that targets the interleukin-5 receptor, which helps reduce the number of eosinophils (a type of white blood cell involved in inflammation) in the body. This makes it particularly effective for patients with severe eosinophilic asthma, a type of asthma that is not well controlled by standard treatments like inhaled corticosteroids and long-acting beta-agonists.12367
What data supports the effectiveness of the drug Benralizumab for asthma?
Who Is on the Research Team?
Mario Castro, MD
Principal Investigator
University of Kansas School of Medicine 3901 Rainbow Blvd. Kansas City, KS 66160, USA
Are You a Good Fit for This Trial?
Adults aged 18-70 with severe eosinophilic asthma, not well-controlled despite using inhaled steroids and long-acting beta agonists. They must have specific levels of blood eosinophils and less than 12 asthma attacks in the past six months. Excluded are those who've had certain treatments like benralizumab or bronchial thermoplasty recently, current smokers, cancer patients, pregnant women, or those on immunosuppressants.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive benralizumab or placebo subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks over a 48-week period
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Benralizumab
Benralizumab is already approved in European Union, United States, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology